WO2002007713A2 - Cilansetron enthaltende arzneimittel zur behandlung nicht-obstipativer männlicher ibs-patienten - Google Patents
Cilansetron enthaltende arzneimittel zur behandlung nicht-obstipativer männlicher ibs-patienten Download PDFInfo
- Publication number
- WO2002007713A2 WO2002007713A2 PCT/EP2001/008260 EP0108260W WO0207713A2 WO 2002007713 A2 WO2002007713 A2 WO 2002007713A2 EP 0108260 W EP0108260 W EP 0108260W WO 0207713 A2 WO0207713 A2 WO 0207713A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cilansetron
- patients
- ibs
- use according
- treatment
- Prior art date
Links
- NCNFDKWULDWJDS-OAHLLOKOSA-N cilansetron Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 NCNFDKWULDWJDS-OAHLLOKOSA-N 0.000 title claims abstract description 37
- 229960002099 cilansetron Drugs 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 title description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 40
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 9
- 229960003550 alosetron Drugs 0.000 claims abstract description 6
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940044551 receptor antagonist Drugs 0.000 claims abstract description 6
- 239000002464 receptor antagonist Substances 0.000 claims abstract description 6
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims abstract description 3
- PWWDCRQZITYKDV-UHFFFAOYSA-N 1-benzyl-2-piperazin-1-ylbenzimidazole Chemical compound C1CNCCN1C1=NC2=CC=CC=C2N1CC1=CC=CC=C1 PWWDCRQZITYKDV-UHFFFAOYSA-N 0.000 claims abstract description 3
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229950005951 azasetron Drugs 0.000 claims abstract description 3
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 claims abstract description 3
- 229960003413 dolasetron Drugs 0.000 claims abstract description 3
- 229960003727 granisetron Drugs 0.000 claims abstract description 3
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims abstract description 3
- MHNNVDILNTUWNS-XYYAHUGASA-N indisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 MHNNVDILNTUWNS-XYYAHUGASA-N 0.000 claims abstract description 3
- 229950007467 indisetron Drugs 0.000 claims abstract description 3
- RWXRJSRJIITQAK-ZSBIGDGJSA-N itasetron Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 claims abstract description 3
- 229950007654 itasetron Drugs 0.000 claims abstract description 3
- 229950009727 lerisetron Drugs 0.000 claims abstract description 3
- 229960005343 ondansetron Drugs 0.000 claims abstract description 3
- 229960003688 tropisetron Drugs 0.000 claims abstract description 3
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- JXQUEAGLZNCBHC-QCUBGVIVSA-N cilansetron hydrochloride Chemical compound O.Cl.CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 JXQUEAGLZNCBHC-QCUBGVIVSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 4
- 235000012054 meals Nutrition 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- -1 ra osetron Chemical compound 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 6
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 abstract description 2
- 229950001588 ramosetron Drugs 0.000 abstract description 2
- FEROPKNOYKURCJ-ZDUSSCGKSA-N 4-amino-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N[C@@H]1C(CC2)CCN2C1 FEROPKNOYKURCJ-ZDUSSCGKSA-N 0.000 abstract 1
- 102000035037 5-HT3 receptors Human genes 0.000 abstract 1
- 108091005477 5-HT3 receptors Proteins 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 2
- 229920003080 Povidone K 25 Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a new medical use of cilansetron or its acid addition salts.
- Cilansetron is a 5HT 3 receptor antagonist, which falls under the scope of the European patent EP 0 297 651 Bl and which has the chemical name (R) - (-) -4, 5, 6, 8, 9, 10- hexahydro- 10- [(2-methyl-lH-imidazol-l-yl) methyl] -llH-pyrido- [3, 2, 1-j] -carbazol-11-one carries.
- European patent EP 0 601 345 B1 already discloses the use of, inter alia, cilansetron for the production of pharmaceutical preparations for the treatment of functional disorders of the lower intestinal tract associated with increased sensitivity to pain and / or abnormally accelerated stool passage in the colon area in larger mammals and humans.
- non-constipative diarrhea-predominant IBS patient group
- WO 99/17755 mentions alosetron, which in clinical trials showed significantly better efficacy in female IBS patients compared to efficacy in male IBS patients. In these clinical trials, male test subjects treated with alosetron did not find any significant improvement in their condition compared to the placebo group.
- cilansetron is stated to be within the scope of the disclosure.
- IBS irritable bowel syndrome
- IBS refers to a group of symptoms associated with pain and / or a feeling of discomfort in the lower abdomen and changed bowel activities such as diarrhea, constipation (constipation) or alternating diarrhea and constipation. Since no clearly definable physiological or other organic findings can be cited as the cause of IBS, the medical diagnosis of this disease is usually based on the absence or presence of a number of symptoms which are generally regarded as typical for IBS and, for example, in the " Ro e Criteria "(cf. WG Thompson et al., Gastroent. Int. 2 (1989) 92-95; WG Thompson et al., Gut 45/11 (1999) II 43 - II 47; WG Thompson, Lancet 341 ( 1993) 1569 - 1572).
- cilansetron can preferably be used in the form of the cilansetron hydrochloride.
- the cilansetron hydrochloride monohydrate is usually used.
- Further pharmacologically acceptable acid addition salts of cilansetron are known from EP 0 297 651 B1.
- BID dosage a dosage of 5HT 3 receptor antagonists
- TID dosage a dosage of IBS patients of both sexes.
- Examples of 5HT 3 receptor antagonists which can be administered more advantageously in triple daily doses include alosetron, azasetron, dolasetron, granisetron, indisetron, itasetron, lerisetron, ondansetron, ramosetron, tropisetron and (R) -zacoprid. It has proven to be particularly advantageous for the treatment of IBS patients of both sexes to administer cilansetron or its pharmacologically acceptable acid addition salts and / or solvates to the patients three times a day, for example in doses between 1 mg and 16 mg per administration.
- cilansetron or a pharmacologically acceptable acid addition salt of cilansetron can be contained according to the invention in solid or liquid pharmaceutical preparations together with customary pharmaceutical auxiliaries and / or carriers.
- solid preparations are orally administrable preparations such as tablets, dragees, capsules, powders or granules or suppositories.
- These preparations can pharmaceutically customary inorganic and / or organic carriers, such as. B. talc, milk sugar or starch in addition to pharmaceutically customary auxiliaries, for example lubricants or tablet disintegrants.
- Liquid preparations such as suspensions or emulsions of cilansetron can contain the usual diluents such as water, oils and / or suspending agents such as polyethylene glycols and the like. Additional auxiliaries can also be added, e.g. B. preservatives, flavor corrections and the like.
- Cilansetron or a pharmacologically acceptable acid addition salt of cilansetron can be mixed and formulated with the pharmaceutical auxiliaries and / or carriers in a manner known per se.
- cilansetron or an acid addition salt can be mixed, for example, with the auxiliaries and / or excipients in a conventional manner and granulated wet or dry. The granules or powder can be filled directly into capsules or pressed into tablet cores in the usual way. If desired, these can be dragged in a known manner.
- the active ingredient is mixed with cornstarch and fine powdered lactose in a mixer.
- the resulting mixture is moistened with a 20% solution of polyvinylpyrolidone (Kollidon 25 R from BASF) in demineralized water. If necessary, further demineralized water is added.
- the moist granulate is passed through a 2 mm sieve. , dried on trays at 40 ° C and then passed through a 1 mm sieve (Frewitt machine). After mixing the granules with magnesium stearate and talc, tablets with a weight of 114 mg are pressed therefrom, so that each tablet contains 4 mg of active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2003-7000038A KR20030019951A (ko) | 2000-07-26 | 2001-07-18 | 변비가 없는 남성 과민성대장증후군 환자의 치료를 위한실란세트론 함유 의약 |
| IL15397201A IL153972A0 (en) | 2000-07-26 | 2001-07-18 | Medicaments containing cilansetron for treating non-obstipated male ibs patients |
| AU2001276409A AU2001276409A1 (en) | 2000-07-26 | 2001-07-18 | Medicaments containing cilansetron for treating non-obstipated male ibs patients |
| MXPA02012917A MXPA02012917A (es) | 2000-07-26 | 2001-07-18 | Medicamentos que contienen cilansetron para el tratamiento de pacientes de ibs masculinos no estre°idos. |
| HU0301479A HUP0301479A2 (hu) | 2000-07-26 | 2001-07-18 | Cilansetron alkalmazása nemobstipációs férfi IBS-betegek kezelésére szolgáló gyógyszerkészítmény elżállítására |
| JP2002513449A JP2004504343A (ja) | 2000-07-26 | 2001-07-18 | 非便秘性の男性ｉｂｓ患者の治療のためのシランセトロン含有医薬品 |
| BR0112690-3A BR0112690A (pt) | 2000-07-26 | 2001-07-18 | Medicamento contendo cilansetron para o tratamento de pacientes ibs masculinos não-obstipativos |
| CA002417677A CA2417677A1 (en) | 2000-07-26 | 2001-07-18 | Medicaments containing cilansetron for treating non-obstipated male ibs patients |
| SK127-2003A SK1272003A3 (en) | 2000-07-26 | 2001-07-18 | Medicaments containing cilansetron for treating non-obstipated male IBS patients |
| EP01954044A EP1307195A2 (de) | 2000-07-26 | 2001-07-18 | Cilansetron enthaltende arzneimittel zur behandlung nicht-obstipativer männlicher ibs-patienten |
| NO20030373A NO20030373D0 (no) | 2000-07-26 | 2003-01-24 | Medikamenter inneholdende cilansetron for behandling av ikke- obstiperte IBS-pasienter av hannkjönn |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10036645.7 | 2000-07-26 | ||
| DE10036645 | 2000-07-26 | ||
| DE10123447.3 | 2001-05-14 | ||
| DE10123447A DE10123447A1 (de) | 2000-07-26 | 2001-05-14 | Cilansetron enthaltende Arzneimittel zur Behandlung nicht-obstipativer männlicher IBS-Patienten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002007713A2 true WO2002007713A2 (de) | 2002-01-31 |
| WO2002007713A3 WO2002007713A3 (de) | 2002-11-14 |
Family
ID=26006529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2001/008260 WO2002007713A2 (de) | 2000-07-26 | 2001-07-18 | Cilansetron enthaltende arzneimittel zur behandlung nicht-obstipativer männlicher ibs-patienten |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1307195A2 (zh) |
| JP (1) | JP2004504343A (zh) |
| CN (1) | CN1444479A (zh) |
| AR (1) | AR028970A1 (zh) |
| AU (1) | AU2001276409A1 (zh) |
| BR (1) | BR0112690A (zh) |
| CA (1) | CA2417677A1 (zh) |
| CZ (1) | CZ2003158A3 (zh) |
| HU (1) | HUP0301479A2 (zh) |
| IL (1) | IL153972A0 (zh) |
| MX (1) | MXPA02012917A (zh) |
| NO (1) | NO20030373D0 (zh) |
| PL (1) | PL363517A1 (zh) |
| RU (1) | RU2003104798A (zh) |
| SK (1) | SK1272003A3 (zh) |
| WO (1) | WO2002007713A2 (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005073220A1 (ja) * | 2004-01-30 | 2005-08-11 | Yamanouchi Pharmaceutical Co., Ltd. | 下痢型過敏性腸症候群治療剤 |
| WO2005072730A1 (ja) * | 2004-01-30 | 2005-08-11 | Astellas Pharma Inc. | 下痢型過敏性腸症候群治療剤 |
| JP2006008707A (ja) * | 2005-09-21 | 2006-01-12 | Astellas Pharma Inc | 下痢型過敏性腸症候群治療剤 |
| US7470690B2 (en) | 2002-07-10 | 2008-12-30 | Dynogen Pharmaceuticals, Inc. | 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601856B2 (en) | 2006-07-27 | 2009-10-13 | Wyeth | Benzofurans as potassium ion channel modulators |
| US7662831B2 (en) | 2006-07-27 | 2010-02-16 | Wyeth Llc | Tetracyclic indoles as potassium channel modulators |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999017755A2 (en) * | 1997-10-07 | 1999-04-15 | Glaxo Group Limited | Medicaments |
| WO2001045685A2 (en) * | 1999-12-20 | 2001-06-28 | Glaxo Group Limited | Formulations of adenosine a1 agonists |
-
2001
- 2001-06-21 AR ARP010102958A patent/AR028970A1/es unknown
- 2001-07-18 MX MXPA02012917A patent/MXPA02012917A/es unknown
- 2001-07-18 CN CN01813307A patent/CN1444479A/zh active Pending
- 2001-07-18 JP JP2002513449A patent/JP2004504343A/ja active Pending
- 2001-07-18 PL PL01363517A patent/PL363517A1/xx not_active Application Discontinuation
- 2001-07-18 BR BR0112690-3A patent/BR0112690A/pt not_active Application Discontinuation
- 2001-07-18 HU HU0301479A patent/HUP0301479A2/hu unknown
- 2001-07-18 AU AU2001276409A patent/AU2001276409A1/en not_active Abandoned
- 2001-07-18 CA CA002417677A patent/CA2417677A1/en not_active Abandoned
- 2001-07-18 RU RU2003104798/15A patent/RU2003104798A/ru not_active Application Discontinuation
- 2001-07-18 SK SK127-2003A patent/SK1272003A3/sk unknown
- 2001-07-18 EP EP01954044A patent/EP1307195A2/de not_active Withdrawn
- 2001-07-18 WO PCT/EP2001/008260 patent/WO2002007713A2/de not_active Application Discontinuation
- 2001-07-18 CZ CZ2003158A patent/CZ2003158A3/cs unknown
- 2001-07-18 IL IL15397201A patent/IL153972A0/xx unknown
-
2003
- 2003-01-24 NO NO20030373A patent/NO20030373D0/no not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999017755A2 (en) * | 1997-10-07 | 1999-04-15 | Glaxo Group Limited | Medicaments |
| WO2001045685A2 (en) * | 1999-12-20 | 2001-06-28 | Glaxo Group Limited | Formulations of adenosine a1 agonists |
Non-Patent Citations (5)
| Title |
|---|
| "Irritable bowel syndrome - Cilansetron." MANUFACTURING CHEMIST, (2000) 71/2 (22)., XP001042043 * |
| BEGLINGER, C. (1) ET AL: "Effect of cilansetron, a specific 5-HT-3 receptor antagonist, on gastrointestinal motor function in normal subjects." NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, (1996) VOL. 353, NO. 4 SUPPL., PP. R163. MEETING INFO.: 37TH SPRING MEETING OF THE GERMAN SOCIETY FOR EXPERIMENTAL AND CLINICAL PHARMACOLOGY AND TOXICOLOGY MAINZ, GERMANY MARCH 12-14, 1996, XP001058426 * |
| BOTELLA, A. ET AL: "Intracolonic glycerol induces abdominal contractions in rats: role of 5-HT3 receptors" FUNDAM. CLIN. PHARMACOL. (1998), 12(6), 619-623, XP001058254 * |
| RABASSEDA, X. ET AL: "Cilansetron" DRUGS FUTURE (1999), 24(5), 475-482, XP001058216 * |
| STACHER, GEORG ET AL: "Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial" BR. J. CLIN. PHARMACOL. (2000), 49(5), 429-436, XP001058300 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7470690B2 (en) | 2002-07-10 | 2008-12-30 | Dynogen Pharmaceuticals, Inc. | 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder |
| WO2005073220A1 (ja) * | 2004-01-30 | 2005-08-11 | Yamanouchi Pharmaceutical Co., Ltd. | 下痢型過敏性腸症候群治療剤 |
| WO2005072730A1 (ja) * | 2004-01-30 | 2005-08-11 | Astellas Pharma Inc. | 下痢型過敏性腸症候群治療剤 |
| JP2006008707A (ja) * | 2005-09-21 | 2006-01-12 | Astellas Pharma Inc | 下痢型過敏性腸症候群治療剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2417677A1 (en) | 2003-01-27 |
| MXPA02012917A (es) | 2003-05-14 |
| WO2002007713A3 (de) | 2002-11-14 |
| NO20030373L (no) | 2003-01-24 |
| RU2003104798A (ru) | 2004-06-27 |
| IL153972A0 (en) | 2003-07-31 |
| CN1444479A (zh) | 2003-09-24 |
| NO20030373D0 (no) | 2003-01-24 |
| SK1272003A3 (en) | 2003-07-01 |
| EP1307195A2 (de) | 2003-05-07 |
| AU2001276409A1 (en) | 2002-02-05 |
| BR0112690A (pt) | 2003-06-24 |
| PL363517A1 (en) | 2004-11-29 |
| CZ2003158A3 (cs) | 2003-08-13 |
| AR028970A1 (es) | 2003-05-28 |
| HUP0301479A2 (hu) | 2003-09-29 |
| JP2004504343A (ja) | 2004-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60103556T3 (de) | Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1-rezeptoren und sibutramine enthalten | |
| DE2523998A1 (de) | Pharmazeutische zubereitung fuer die behandlung der schizophrenie | |
| EP0752246A2 (de) | Kappa-Opiate für entzündliche Darmerkrankungen | |
| DE2823174A1 (de) | Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose | |
| DE69420776T2 (de) | Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer | |
| DE60030654T2 (de) | Verwendung von Lasofoxifen | |
| US6566369B2 (en) | Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients | |
| DE3415394A1 (de) | Medikament gegen ovarialinsuffizienz | |
| DE60219940T2 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| WO2002007713A2 (de) | Cilansetron enthaltende arzneimittel zur behandlung nicht-obstipativer männlicher ibs-patienten | |
| DE60204694T2 (de) | Kombinationstherapie zur behandlung von herzinsuffizienz | |
| DE602004005734T2 (de) | Pharmazeutische zusammensetzung mit kontrollierter freisetzung und verfahren zu ihrer herstellung | |
| DE69522764T2 (de) | Verwendung vom einem Bicycloheptan-Derivat | |
| DE69907387T2 (de) | Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von refraktärer Vasculitis. | |
| DE69625210T2 (de) | Nicorandil gegen angstneurosen | |
| TWI289060B (en) | Pharmaceutical composition for improving the recovery of post-stroke patients | |
| DE69004529T2 (de) | Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen. | |
| WO2002080905A1 (de) | Kappa-opiatagonisten für die behandlung von erkrankungen der blase | |
| EP1001756A1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE60112750T2 (de) | Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen | |
| EP2120918B1 (de) | Pharmazeutische zusammensetzung zur behandlung von inkontinenz | |
| DE10123447A1 (de) | Cilansetron enthaltende Arzneimittel zur Behandlung nicht-obstipativer männlicher IBS-Patienten | |
| DE2823267C2 (zh) | ||
| DE2823268A1 (de) | Blutdrucksenkendes mittel | |
| DE3317280C2 (zh) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/012917 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020037000038 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 153972 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200300445 Country of ref document: ZA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PV2003-158 Country of ref document: CZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 01813307X Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2417677 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2001954044 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1272003 Country of ref document: SK |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 523959 Country of ref document: NZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2001276409 Country of ref document: AU Ref document number: 198/MUMNP/2003 Country of ref document: IN |
|
| ENP | Entry into the national phase |
Ref document number: 2003104798 Country of ref document: RU Kind code of ref document: A Ref country code: RU Ref document number: RU A |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020037000038 Country of ref document: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: 2001954044 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: PV2003-158 Country of ref document: CZ |
|
| WWR | Wipo information: refused in national office |
Ref document number: PV2003-158 Country of ref document: CZ |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2001954044 Country of ref document: EP |